Clinical characteristics and outcomes of Chinese patients with KRAS-mutant non-small cell lung cancer after chemotherapy

被引：2
|
作者：
Zheng, Yawen [1 ,2 ]
Lai, Qinghua [1 ]
Zhao, Hanxi [2 ]
Li, Xiaolin [2 ]
Sun, Xiaorong [2 ]
Xing, Ligang [2 ]
机构：
[1] Shandong First Med Univ, Cent Hosp, Shandong Univ, Dept Oncol,Jinan Cent Hosp,Cheeloo Coll Med, Jinan 250013, Shandong, Peoples R China
[2] Shandong First Med Univ & Shandong Acad Med Sci, Shandong Canc Hosp & Inst, Shandong Key Lab Radiat Oncol, Dept Radiat Oncol, 440 Jiyan Rd, Jinan 250117, Shandong, Peoples R China
来源：
CANCER COMMUNICATIONS | 2021年 / 41卷 / 11期
关键词：
D O I：
10.1002/cac2.12227
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1234 / 1238
页数：5
相关论文
共 50 条
  • [21] KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
    Rosell, Rafael
    Jantus-Lewintre, Eloisa
    Cao, Peng
    Cai, Xueting
    Xing, Baojuan
    Ito, Masaoki
    Gomez-Vazquez, Jose Luis
    Marco-Jordan, Mireia
    Calabuig-Farinas, Silvia
    Cardona, Andres Felipe
    Codony-Servat, Jordi
    Gonzalez, Jessica
    Valencia-Clua, Kevin
    Aguilar, Andres
    Pedraz-Valdunciel, Carlos
    Dantes, Zahra
    Jain, Anisha
    Chandan, S.
    Molina-Vila, Miguel Angel
    Arrieta, Oscar
    Ferrero, Macarena
    Camps, Carlos
    Gonzalez-Cao, Maria
    [J]. CELL COMMUNICATION AND SIGNALING, 2024, 22 (01)
  • [22] Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
    Acquaviva, Jaime
    Smith, Donald L.
    Sang, Jim
    Friedland, Julie C.
    He, Suqin
    Sequeira, Manuel
    Zhang, Chaohua
    Wada, Yumiko
    Proia, David A.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2012, 11 (12) : 2633 - 2643
  • [23] Role of imunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival
    Amanam, Idoroenyi
    Mambetsariev, Isa
    Gupta, Rohan
    Achuthan, Srisairant
    Wang, Yingyu
    Pharaon, Rebecca
    Massarelli, Erminia
    Koczywas, Marianna
    Reckamp, Karen
    Salgia, Ravi
    [J]. JOURNAL OF THORACIC DISEASE, 2020, 12 (09) : 5086 - +
  • [24] Efficacy of immune checkpoint inhibitors in patients with KRAS-mutant advanced non-small cell lung cancer: A retrospective analysis
    Gu, Xiaodong
    Si, Jinfei
    Guan, Yelan
    Xu, Yibing
    Shao, Lan
    Zhang, Yiping
    Xu, Chunwei
    Pan, Weiwei
    Lu, Yuanzhi
    Song, Zhengbo
    Wang, Wenxian
    [J]. OPEN MEDICINE, 2023, 18 (01):
  • [25] Outcomes of Molecular Characteristics in Chinese BAP1-Mutant Non-Small Cell Lung Cancer Patients
    Ke, H.
    Xu, C.
    Wang, W.
    Zhang, Q.
    Zhuang, W.
    Zhu, Y.
    Huang, Y.
    Chen, G.
    Fang, M.
    Lv, T.
    Song, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S960 - S960
  • [26] Clinicopathologic characteristics and outcomes for patients with KRAS G12D-mutant non-small cell lung cancer (NSCLC).
    Cooper, Alissa Jamie
    Muzikansky, Alona
    Lennerz, Jochen K.
    Mino-Kenudson, Mari
    Hung, Yin P.
    Piotrowska, Zofia
    Dagogo-Jack, Ibiayi
    Sequist, Lecia V.
    Lin, Jessica Jiyeong
    Gainor, Justin F.
    Heist, Rebecca Suk
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [27] Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations
    Davis, Alexander P.
    Cooper, Wendy A.
    Boyer, Michael
    Lee, Jenny H.
    Pavlakis, Nick
    Kao, Steven C.
    [J]. IMMUNOTHERAPY, 2021, 13 (11) : 941 - 952
  • [28] Phase I study of lapatinib plus trametinib in patients with KRAS-mutant colorectal, non-small cell lung, and pancreatic cancer
    Huijberts, Sanne C. F. A.
    van Geel, Robin M. J. M.
    van Brummelen, Emilie M. J.
    Opdam, Frans L.
    Marchetti, Serena
    Steeghs, Neeltje
    Pulleman, Saskia
    Thijssen, Bas
    Rosing, Hilde
    Monkhorst, Kim
    Huitema, Alwin D. R.
    Beijnen, Jos H.
    Bernards, Rene
    Schellens, Jan H. M.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (05) : 917 - 930
  • [29] Genomic pathogenic alterations of the SWI/SNF complex genes compromise the outcomes to immunotherapy in Chinese KRAS-mutant non-small cell lung cancer by downregulated STING
    Gao, Lingling
    Jiang, Jie
    Xie, Zhi
    Zhu, Linlin
    Chen, Yu
    Lv, Zhiyi
    Chen, Yuqing
    Zhou, Wenbin
    Chen, Ji
    Zhong, Yumin
    Zhang, Li
    Zeng, Penghui
    Huang, Xiaodan
    Yan, Wenqing
    Lu, Danxia
    Zhang, Shuilian
    Guo, Weibang
    Zhang, Xuchao
    [J]. CANCER RESEARCH, 2024, 84 (06)
  • [30] The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy
    Shu, Chun-Lu
    Liu, Yu -Ling
    [J]. CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 3485 - 3492
12345